Richard Dodel1, Mark Belger2, Catherine Reed3, Anders Wimo4, Roy W Jones5, Michael Happich2, Josep M Argimon6, Giuseppe Bruno7, Bruno Vellas8, Josep Maria Haro9. 1. Department of Neurology, Philipps-University, Marburg, Germany. 2. Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, Surrey, UK. 3. Eli Lilly and Company Limited, Lilly Research Centre, Windlesham, Surrey, UK. Electronic address: reed_catherine@lilly.com. 4. Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. 5. RICE - The Research Institute for the Care of Older People, The RICE Centre, Royal United Hospital, Bath, UK. 6. Agencia Qualitat i Avaluació Sanitaries, Barcelona, Spain. 7. Clinica della Memoria, Department of Neurological Sciences, University of Rome "Sapienza", Rome, Italy. 8. Gerontopole, Alzheimer's Disease Research and Clinical Center, INSERM 1027, Toulouse University Hospital, Toulouse, France. 9. Parc Santari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
Abstract
BACKGROUND: To identify the main factors associated with societal costs of Alzheimer's disease (AD) in community-dwelling patients across three European countries. METHODS: Baseline cost data from a prospective, observational study were used. Assessments included patients' cognition, activities of daily living (ADLs) and behavioral symptoms, and caregiver burden. Cost calculations (2010) from the societal perspective were based on patient/caregiver resource use. Generalized linear models estimated factors associated with costs. RESULTS: Mean monthly costs per patient differed for France (€1881), Germany (€2349), and the UK (€2016), with informal care costs accounting for 50% to 61%. Independent factors associated with costs across all countries were ADL total score, patient living arrangements, caregiver working status, and caregiver burden (all P < .05). Additional factors were significant for the pooled cohort or individual countries. CONCLUSIONS: Several patient and caregiver factors, including factors associated with informal care, should be included when evaluating care options for patients with AD.
BACKGROUND: To identify the main factors associated with societal costs of Alzheimer's disease (AD) in community-dwelling patients across three European countries. METHODS: Baseline cost data from a prospective, observational study were used. Assessments included patients' cognition, activities of daily living (ADLs) and behavioral symptoms, and caregiver burden. Cost calculations (2010) from the societal perspective were based on patient/caregiver resource use. Generalized linear models estimated factors associated with costs. RESULTS: Mean monthly costs per patient differed for France (€1881), Germany (€2349), and the UK (€2016), with informal care costs accounting for 50% to 61%. Independent factors associated with costs across all countries were ADL total score, patient living arrangements, caregiver working status, and caregiver burden (all P < .05). Additional factors were significant for the pooled cohort or individual countries. CONCLUSIONS: Several patient and caregiver factors, including factors associated with informal care, should be included when evaluating care options for patients with AD.
Authors: May A Beydoun; Alyssa A Gamaldo; Hind A Beydoun; Danielle Shaked; Alan B Zonderman; Shaker M Eid Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Mark Belger; Josep Maria Haro; Catherine Reed; Michael Happich; Kristin Kahle-Wrobleski; Josep Maria Argimon; Giuseppe Bruno; Richard Dodel; Roy W Jones; Bruno Vellas; Anders Wimo Journal: BMC Med Res Methodol Date: 2016-07-18 Impact factor: 4.615
Authors: Frida Svedin; Anders Brantnell; Paul Farrand; Oscar Blomberg; Chelsea Coumoundouros; Louise von Essen; Anna Cristina Åberg; Joanne Woodford Journal: BMJ Open Date: 2021-07-16 Impact factor: 2.692